Immunomedics and Johnson Matthey Announce Strategic Manufacturing Partnership

Immunomedics, Inc., and Johnson Matthey, today announced the companies have expanded their long-term master supply agreement under which Johnson Matthey will continue to scale the manufacturing of CL2A-SN-38, the drug-linker that is a key component of sacituzumab govitecan, Immunomedics lead antibody-drug conjugate currently under priority review by the FDA for accelerated approval as a treatment for patients with metastatic triple-negative breast cancer. This is part of Immunomedics ongoing commitment to invest in and scale its global supply capacity with world-class partners in each component of its supply-chain.
“We are significantly scaling our ongoing partnership with Johnson Matthey,” said Dr. Morris Rosenberg, Chief Technology Officer of Immunomedics. “This agreement signifies our continuing commitment to expand our supply-chain strategy as we look to broaden the applicability of sacituzumab govitecan to a multitude of solid cancer indications and expand it to other world markets.”